A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases

By Lin Nancy   Freedman Rachel   Ramakrishna Naren   Younger Jerry   Storniolo Anna   Bellon Jennifer   Come Steven   Gelman Rebecca   Harris Gordon   Henderson Mark   MacDonald Shannon   Mahadevan Anand   Eisenberg Emily   Ligibel Jennifer   Mayer Erica   Moy Beverly   Eichler April   Winer Eric  

Breast Cancer Research and Treatment, Vol. 142, Iss. 2, 2013-11 ,pp. : 405-414

Springer Publishing Company

Access to resources Recommend Favorite

HER2-positive Breast Cancer Brain Metastases: Multiple Responses to Systemic Chemotherapy and Trastuzumab—a Case Report

By Church D.   Bahl A.   Jones A.   Price C.  

Journal of Neuro-Oncology, Vol. 79, Iss. 3, 2006-09 ,pp. : 289-292

Springer Publishing Company

Access to resources Recommend Favorite

Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts

By Bartolotti Marco   Franceschi Enrico   Brandes Alba A  

Future Oncology, Vol. 9, Iss. 11, 2013-11 ,pp. : 1653-1664

Future Medicine

Access to resources Recommend Favorite

A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients

By Iwata Hiroji   Narabayashi Masaru   Ito Yoshinori   Saji Shigehira   Fujiwara Yasuhiro   Usami Shigeyuki   Katsura Koichi   Sasaki Yasutsuna  

International Journal of Clinical Oncology, Vol. 18, Iss. 4, 2013-08 ,pp. : 621-628

Springer Publishing Company

Access to resources Recommend Favorite

Phospho-PRAS40Thr246 predicts trastuzumab response in patients with HER2-positive metastatic breast cancer

By  

Oncology Letters, Vol. 9, Iss. 2, 2015-01 ,pp. : 785-789

Spandidos Publications

Access to resources Recommend Favorite